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is mediated by the FGFR2b recep-
tor isoform in vivo and only signals 
weakly through the FGFR1b isoform 
(Ornitz and Itoh, 2001; Zhang et al., 
2006). One possible explanation is 
that high levels of FGF10 may be suf-
ficient to activate FGFR1 in vivo—fur-
ther analyses of FGF10 signaling in 
the prostate will undoubtedly shed 
additional light on this issue.
In summary, the two new manu-
scripts in this issue of Cancer Cell 
indicate that paracrine actions of FGF 
signaling between stromal and epi-
thelial compartments may be critical 
for prostate tumorigenesis, as has 
long been proposed in the literature. 
These provocative studies open new 
avenues for further research, particu-
larly to determine how FGFR pathway 
activation can drive EMT and promote 
metastasis. Notably, the interactions 
between FGFR signaling and the AR 
and Akt pathways during prostate 
tumorigenesis suggest that poten-
tially valuable therapeutic strategies 
may exist for targeting FGF recep-
tors in conjunction with Akt or related 
pathway inhibitors.
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The identification of genes that contribute to the oncogenic process, including those that determine 
risk of cancer onset, holds the key not only in understanding mechanisms of oncogenesis but also 
in the identification of new targets for therapeutic development. Traditional methods of genetics 
and molecular biology have been successful but are slow and laborious. The advent of genome 
technologies, leading to the generation of large data sets describing various properties of genes 
and proteins relevant to cancer phenotypes, has afforded a new opportunity for discovery. M. Vidal 
and colleagues have made use of this data, and in particular the integration of various forms of 
genome-scale data, to identify new genes involved in breast cancer.The development of technologies 
that facilitate genome-scale analyses 
of gene expression, DNA sequence 
variation, protein accumulation, pro-
tein interactions, DNA copy number, 
and more has had a transforming 
effect on biology and medicine. This 
is perhaps best seen in cancer, where complex data sets have been coupled 
with powerful analytical methods to 
extract a level of detail of the under-
lying biology not achievable with the 
once powerful methods of molecu-
lar biology. As an example, the use 
of large-scale gene expression data 
has dissected cancer into a variety of Cancer Cell 12, subtypes that begin to address the 
full complexity of the disease, recog-
nizing that lymphoma, breast cancer, 
and others are not single diseases, or 
even two or three diseases, but rather 
a vast array of complex diseases 
defined by a variety of genetic altera-
tions (Alizadeh et al., 2000; Golub et December 2007 ©2007 Elsevier Inc. 497
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Previewsal., 1999; Perou et al., 2000). 
Although in many instances, 
these complex data sets 
have been developed for the 
purpose of a specific study 
such as the ability to predict 
breast cancer recurrence 
or to identify lymphoma 
subtypes that represent 
distinct disease entities, or 
to predict the response to 
specific therapeutic regi-
mens, others have been 
generated for the purpose 
of large-scale descriptions 
of gene expression, protein 
interaction, and other char-
acteristics without regard 
to a specific context. Either way, they 
represent a resource of data that 
describes the biological complex-
ity of the disease state in question. 
As such, they represent potentially 
enormously valuable resources of 
information that can form the basis 
for discovery of new disease mecha-
nisms and ultimately new targets for 
cancer therapy.
A recent study by Marc Vidal and 
colleagues, published in Nature 
Genetics, describes a strategy to 
take advantage of this available data 
and link it in a way that allows for 
discovery of genes not previously 
recognized to play a role in a par-
ticular process (Pujana et al., 2007). 
The context in this case is breast 
cancer, starting from the genes 
identified in genetic studies to con-
fer increased susceptibility to breast 
cancer—BRCA1 and BRCA2. These 
were combined with two additional 
genes—ATM and CHEK2, genes 
also known to confer risk of breast 
cancer, albeit at much lower pen-
etrance—as the starting point in a 
genomic data search for additional 
activities contributing to breast can-
cer risk. Importantly, each of these 
gene products is involved in a func-
tional pathway of DNA damage rec-
ognition and repair. As such, the 
common function provided a basis 
for search for additional genes with 
shared properties that might then 
lead to additional genes involved 
in breast cancer susceptibility. The 
logic of the approach to utilizing these 
resources is relatively simple. If two 
genes are known to share expression 
properties across diverse circum-
stances, they might represent genes 
with shared function. But if they also 
are known to encode proteins that 
physically interact, or that geneti-
cally interact, then the likelihood that 
they share function increases sub-
stantially. The power of this strategy 
lies in the availability of diverse data 
sets describing various properties 
of genes and gene products—DNA 
sequence variation, chromosomal 
alterations, gene expression, protein 
interactions, and more.
The starting point in this search 
was the use of gene expression 
data from normal human breast 
tissue. The concept is straightfor-
ward—genes that share expression 
properties across a large number of 
biological samples might also share 
function, an approach applied pre-
viously as a basis for discovery of 
similar function (Stuart et al., 2003). 
Various methods for analyzing this 
data, and identifying coexpression 
networks, can be employed; Vidal 
and colleagues used a simple deter-
mination of correlation coefficient. 
In this case, the goal is to identify 
expression patterns that might yield 
functionally related gene products. 
Evidence that the coexpression data 
did yield genes of interest was sug-
gested by an enrichment for func-
tional interactions evident in a litera-
ture search as well as shared Gene 
Ontology terms.
Obviously, this one piece 
of data alone would not be 
sufficient. Genes that are 
coexpressed are candi-
dates for further study, but 
the number of such genes is 
very large. It is at this point 
that the real power of the 
strategy comes into play, by 
combining these patterns of 
gene expression covariation 
with other equally powerful 
data sets such as protein 
accumulation, genetic inter-
actions, and protein inter-
actions (Figure 1). Such an 
analysis of a BRCA1-based 
network led to the identifica-
tion of the hyaluronan-mediated motil-
ity receptor gene (HMMR) as a com-
ponent of the network with the highest 
correlation with BRCA1 expression. 
HMMR was found to interact with 
components of the centrosome, and 
further analysis demonstrated an inter-
action of BRCA1 with the centrosome, 
specifically as cells enter mitosis.
Of course, even with the com-
pelling nature of the data intersec-
tions that point toward HMMR as a 
BRCA1-related activity, this is never-
theless only a candidate. The power 
in the data intersection approach is 
to generate such candidates with 
high probability of being involved in 
the process of interest. Nevertheless, 
proof of a role for the gene in breast 
cancer and DNA repair requires 
experimental validation. Vidal and 
colleagues took two approaches 
to providing such validation. First, 
siRNA-based knockdown of HMMR 
resulted in an increase in centro-
some number; importantly, the 
same phenotype was obtained upon 
knockdown of BRCA1. Second, and 
most importantly in the context of 
identification of new risk-associated 
genes, an analysis of DNA sequence 
variation (SNPs) in the HMMR gene 
demonstrated a link with breast can-
cer susceptibility, independent of 
BRCA1 status. In particular, multiple 
SNPs within the HMMR locus were 
associated with risk in multiple inde-
pendent cohorts of breast cancer 
patients. Moreover, further analyses 
indicated a link between expression 
figure 1. Integration of Multiple Genome-scale Data sets for 
Discovery
The schematic depicts the utilization of multiple data sets describing 
gene expression, protein interaction, and other forms of large-scale 
data to search for interactions that are evident in multiple states.498 Cancer Cell 12, December 2007 ©2007 Elsevier Inc.
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expression of HMMR was associated 
with an early age of diagnosis.
With a starting point of examin-
ing BRCA1 coexpression, and then 
expanding through the analysis of 
physical and functional intersec-
tions observed in various com-
plex data sets, a new breast can-
cer gene has emerged that now 
extends the function of the major 
breast cancer susceptibility genes 
and provides the basis for further 
study. Perhaps most important is 
the demonstration of a strategy 
that can make use of the wealth of 
accumulating genome-scale data 
for in silico discovery. The oppor-
tunities for exploiting these data 
sets with a strategy such as that 
elaborated by Vidal and colleagues 
is only limited by the question to 
be addressed and a knowledge of 
the appropriate starting point in the search. Other recent examples can 
be seen in the connection of gene 
expression signatures with cancer 
genome alterations as a mechanism 
to identify genes linked to the rel-
evant cancer phenotypes. This has 
led to the identification of Myc and 
Jab1 amplification in breast can-
cer based on a link with a wound 
response expression signature 
(Adler et al., 2006) and identifica-
tion of the MITF transcription factor 
as a melanoma oncogene based on 
expression properties linked to a 
melanoma gene amplification pro-
file (Garraway et al., 2005). As with 
the example of the identification 
of HMMR as a new breast cancer 
gene, these further studies highlight 
the identification of genes based on 
an integration of powerful data sets 
and analytical tools. We have every 
reason to believe that more is to be 
mined with these tools.Cancer Cell 12, DRefeRences
Adler, A.S., Lin, M., Horlings, H., Nuyten, D.S., 
van de Vijver, M.J., and Chang, H.Y. (2006). 
Nat. Genet. 38, 421–430.
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, 
C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., 
Sabet, H., Tran, T., Yu, X., et al. (2000). Nature 
403, 503–511.
Garraway, L.A., Widlund, H.R., Rubin, M.A., 
Getz, G., Berger, A.J., Ramaswamy, S., Ber-
oukhim, R., Milner, D.A., Granter, S.R., Du, J., 
et al. (2005). Nature 436, 117–122.
Golub, T.R., Slonim, D.K., Tamayo, P., Huard, 
C., Gaasenbeek, M., Mesirov, J.P., Coller, H., 
Loh, M.L., Downing, J.R., Caligiuri, M.A., et al. 
(1999). Science 286, 531–537.
Perou, C.M., Sorlie, T., Eisen, M.B., van de 
Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, 
J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et 
al. (2000). Nature 406, 747–752.
Pujana, M.A., Han, J.-D.J., Starita, L.M., Ste-
vens, K.N., Tewari, M., Ahn, J.S., Rennert, G., 
Morena, V., Kirchhoff, T., Gold, B., et al. (2007). 
Nat. Genet. 39, 1338–1349.
Stuart, J.M., Segal, E., Koller, D., and Kim, S.K. 
(2003). Science 302, 249–255.ecember 2007 ©2007 Elsevier Inc. 499
